在白血病干细胞中出现BET抑制剂耐药性
Chun Yew Fong1,2,3, Omer Gilan1,2, Enid Y N Lam1
1Cancer Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Nature
|September 15, 2015
概括
在急性髓性白血病中,代蛋白和额外终端蛋白 (BET) 抑制剂具有前景. 从白血病干细胞中产生耐药性,部分原因是Wnt/β-catenin信号的增加,这种信号可以被向恢复药物敏感性.
科学领域:
- 癌症学
- 分子生物学
- 药理学
背景情况:
- 代蛋白和额外终端蛋白 (BET) 抑制剂是针对癌症的新型向疗法.
- 临床试验显示BET抑制剂具有前景,特别是在急性髓性白血病 (AML) 中.
- 了解耐药机制对于优化BET抑制剂的疗效至关重要.
研究的目的:
- 在小鼠的造血干细胞和原始细胞中研究BET抑制剂I-BET的耐药性机制.
- 在白血病中确定克服BET抑制剂耐药性的策略.
主要方法:
- 从MLL-AF9永久化小鼠血造干细胞和前代细胞生成I-BET耐药单细胞克隆.
- 评估对其他BET抑制剂的交叉耐药性和遗传性冲击.
- 分析染色体结合的BRD4水平和关键基因表达 (例如Myc).
- 研究了Wnt/β-catenin信号传递在耐药性的作用.
主要成果:
- 对其他BET抑制剂的交叉耐药性和基因倒退.
- 抗药性来自白血病干细胞,而不是由于药物排放或代谢.
- 观察到与染色体结合的BRD4总体减少,Myc表达没有改变.
- 增加Wnt/β-catenin信号被确定为小鼠和人类白血病细胞中抗性的关键机制.
结论:
- 在AML中对BET抑制剂的耐药性部分由增强的Wnt/β-catenin信号介导.
- 向Wnt/β-catenin信号可以恢复对BET抑制剂的敏感性.
- 这些发现为AML生物学提供了洞察力,并提出了改善BET抑制剂治疗的策略.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
6.4K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Stem Cell Therapy for Tissue Regeneration
4.9K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.9K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K


